

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: 1-16-02

By: Janessa Gaud



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Lau, *et al.*

SERIAL NO.: 09/660,468

FILED: September 12, 2000

FOR: **CYTOKINE COMPOSITION AND  
METHOD OF ITS PRODUCTION**

EXAMINER: Romeo, David S.

ART UNIT: 1647

TECH CENTER 1600/2900

FEB 06 2002

RECEIVED

Amendment in Response to Restriction Requirement

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated December 17, 2001, please amend the application as follows.

In the Claims

Please cancel claims 11-24 without prejudice.

Please add new claims 25-29 as follows:

25. The composition of claim 1, for use as a therapeutic composition, wherein the cytokines-isolated are selected from the group consisting of IL-1-alpha, IL-1-beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-13, IL-1 receptor antagonist (IL-1ra), IFN-alpha, IFN-beta, IFN-gamma, oncostatin, TNF-alpha, TNF-beta, soluble TNF receptor (sTNFR), GM-CSF, G-CSF, and M-CSF.

26. The composition of claim 25, wherein the isolated cytokines comprises IFN-alpha and IFN-beta.

27. The composition of claim 25, wherein the isolated cytokines comprises IFN-beta and IFN-gamma.

28. The composition of claim 25, wherein the isolated cytokines comprises IFN-alpha and IFN-gamma.